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Abstract Oritavancin, telavancin, and dalbavancin are
recently marketed lipoglycopeptides that exhibit remarkable
differences to conventional molecules. While dalbavancin
inhibits the late stages of peptidoglycan synthesis by mainly
impairing transglycosylase activity, oritavancin and tela-
vancin anchor in the bacterialmembrane by the lipophilic side
chain linked to their disaccharidic moiety, disrupting mem-
brane integrity and causing bacteriolysis. Oritavancin keeps
activity against vancomycin-resistant enterocococci, being a
stronger inhibitor of transpeptidase than of transglycosylase
activity. These molecules have potent activity against Gram-
positive organisms, most notably staphylococci (including
methicillin-resistant Staphylococcus aureus and to some
extent vancomycin-intermediate S. aureus), streptococci
(including multidrug-resistant pneumococci), and Clostridia.
All agents are indicated for the treatment of acute bacterial
skin and skin structure infections, and telavancin, for hospital-
acquired and ventilator-associated bacterial pneumonia.
While telavancin is administered daily at 10 mg/kg, the
remarkably long half-lives of oritavancin and dalbavancin
allow for infrequent dosing (single dose of 1200 mg for ori-
tavancin and 1000 mg at day 1 followed by 500 mg at day 8
for dalbavancin), which could be exploited in the future for
outpatient therapy. Among possible safety issues evidenced
during clinical development were an increased risk of devel-
oping osteomyelitis with oritavancin; taste disturbance,
nephrotoxicity, and risk of correctedQT interval prolongation
(especially in the presence of at-risk co-medications) with
telavancin; and elevation of hepatic enzymes with dalba-
vancin. Interference with coagulation tests has been reported
with oritavancin and telavancin. These drugs proved non-in-
ferior to conventional treatments in clinical trials but their
advantagesmay be better evidenced upon future evaluation in
more severe infections.
Key Points
New lipoglycopeptides (telavancin, oritavancin,
dalbavancin) differ from vancomycin by the
presence of a lipophilic side chain, which profoundly
modifies their pharmacokinetic and/or
pharmacodynamic profile.
Among these agents, telavancin and oritavancin have
multiple modes of action and are highly bactericidal.
Oritavancin and dalbavancin have prolonged half-
lives, allowing for their use a single-dose or two-
dose (once-a-week) regimen, respectively.
These three drugs are indicated for the treatment of
acute bacterial skin and skin structure infections, and
telavancin is indicated for hospital-acquired and
ventilator-associated bacterial pneumonia.
1 Introduction
Glycopeptide antibacterials (vancomycin, teicoplanin)
were introduced on the market as early as the 1950s and
1980s, respectively. Over the last 6 years, three new
drugs have been registered and commercialized (see
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Fig. 1 Chemical structure of new glycopeptides as compared to
conventional molecules. Substituents that are positively charged at
physiological pH are highlighted in blue and those that are negatively
charged are highlighted in red. The a-carbon atom of each residue is
numbered in vancomycin. Lipophilic side chains conferring bacteri-
cidal character to oritavancin and telavancin are marked by black
arcs. The additional sugar allowing for cooperative binding in
oritavancin is pointed to by a black arrow
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Fig. 1 for their chemical structures) and are referred to
as lipoglycopeptides because they possess an additional
lipophilic side chain compared with vancomycin. Among
them, telavancin and oritavancin are very innovative, as
they show an additional mode of action and a rapidly
bactericidal character due to the presence of this lipo-
philic side chain attached to the disaccharide moiety. On
the other hand, dalbavancin, the lipophilic side chain of
which is located on the same position as that found in
teicoplanin, shows an improved pharmacokinetic profile
but the same mode of action as teicoplanin. This review
compares the microbiological and pharmacological
properties, clinical use, and potential usefulness of these
three molecules with those of vancomycin. A PubMed
search was performed using the keywords oritavancin (or
LY333328), telavancin (or TD-6424), dalbavancin (or
BI397). All papers published over the last 5 years were
examined. Older papers were also considered if dealing
with discovery, pharmacokinetics, pharmacodynamics,
mode of action, clinical trials, or toxicity.
2 Discovery and History
2.1 Oritavancin
Oritavancin is a semi-synthetic derivative of the naturally
occurring lipoglycopeptide chloroeremomycin. Chloroere-
momycin differs from vancomycin by the presence of an
additional aminated sugar (4-epi-vancosamine) on the
amino acid 6 of the cyclic heptapeptide and the replace-
ment of the 4-vancosamine by a 4-epi-vancosamine in the
disaccharide attached to the aglycone moiety [1]. In ori-
tavancin, the addition of a chlorobiphenylmethyl side chain
to this disaccharide is responsible for the amphipathic
character of the molecule.
Oritavancin was discovered at Eli Lilly [1] as
LY333328 (see Allen [2] for a full history of this
molecule). It was selected as a candidate for clinical
development in 1994 based on its excellent activity
in vitro and in vivo as well as on a favorable pharma-
cokinetic profile. After Eli Lilly decided to terminate its
activities in the field of anti-infective drugs, oritavancin
was transferred to InterMune (San Francisco, CA, USA)
in 2002, where additional phase I trials were conducted.
InterMune also decided to re-focus its activities and sold
the molecule to Targanta Therapeutics (Montreal, QC,
Canada) in 2006. Many additional in vitro investigations
were performed at that time that better documented the
mechanism of action of the drug as well as its activity in
specific models of infection. Data from additional phase I
and II trials suggest that infrequent dosing could be used
and effective [3, 4].
In 2008, Targanta submitted new drug applications to
the US Food and Drug Administration (FDA) and Euro-
pean Medicines Agency (EMA), with a dosing scheme of
1.5–3 mg/kg/day for 3–7 days [5]. These applications were
not accepted because of insufficient clinical evidence of
efficacy and safety. The Medicines Company (Parsippany,
NJ, USA) acquired oritavancin in 2009, completed addi-
tional pharmacological investigations, and ran phase III
trials with an innovative therapeutic scheme that eventually
led to the registration of the drug for the treatment of
complicated skin and skin structure infections by both the
American and European Agencies in 2014 [6, 7].
2.2 Telavancin
Telavancin is a semi-synthetic derivative of vancomycin,
in which a hydrophobic (decylaminoethyl) side chain is
added to the disaccharide. A phosphonomethy-
laminomethyl substituent on the cyclic peptidic core
counterbalances to some extent the hydrophobicity brought
by this lipophilic side chain. The molecule was named TD-
6424 by Theravance [now Theravance BioPharma (San
Francisco, CA, USA)] [8]. Remarkably, this small com-
pany was able to conduct the preclinical and clinical
development of the molecule internally in a streamlined
fashion (through strategic collaborations with pharmaceu-
tical companies including Astellas Pharma Inc.) and
obtained marketing authorization by the FDA in 2009 for
the treatment of complicated skin and skin structure
infections and by the EMA in 2011 for the treatment of
hospital-acquired pneumonia (see Wenzler and Rodvold
[9] for a recent review on the discovery and history of the
development of this compound). Telavancin was the first
marketed product for this company. In situations where
other alternatives are not suitable, the accepted indications
in the USA now include both complicated skin and skin
structure infections and hospital-acquired and ventilator-
associated bacterial pneumonia (HABP/VABP) caused by
susceptible isolates of Staphylococcus aureus [10], and in
Europe include nosocomial pneumonia, including ventila-
tor-associated pneumonia that is known or suspected to be
caused by methicillin-resistant S. aureus (MRSA) [11].
2.3 Dalbavancin
Dalbavancin (BI397) is a semi-synthetic derivative from
the natural glycopeptide A40926. A40926 differs from
teicoplanin by the absence of the acetylglucosamine in the
benzylic position, the replacement of the acylglucosamine
in position 4 by an acylaminoglucuronic acid, the length of
the fatty acid chain, the position of one chlorine atom, and
the terminal methylamino group [12]. In dalbavancin, the
peptide carboxy group of A40926 has been replaced by a
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3,3-dimethylaminopropylamide [13]. Dalbavancin was
discovered by Biosearch and out-licensed for North
America to Versicor. Both companies then merged to
create Vicuron Pharmaceuticals (King of Prussia, PA,
USA) and continued to develop the product. Vicuron was
acquired by Pfizer in 2005, which pursued the development
of dalbavancin to the point where the FDA requested
additional clinical data before approval. In 2009, the drug
was then acquired by Durata Therapeutics (Chicago, IL,
USA), which initiated new phase III trials. The drug was
approved by the FDA in 2014 and by the EMA in 2015 for
the treatment of complicated skin and skin structure
infections [14, 15]. Durata Therapeutics was acquired by
Actavis (Parsippany, NJ, USA) in 2014, which commer-
cializes dalbavancin today (see Butler et al. [16] for a
review of this history).
3 Activity
3.1 Mechanism of Action and of Resistance
for Conventional Glycopeptides
Conventional glycopeptides inhibit the late stages of pep-
tidoglycan synthesis (Fig. 2). Via their aglycone moiety,
they establish five hydrogen bounds with the D-Ala-D-Ala
termini of pentapeptidic precursors, which by steric hin-
drance prevents the transglycosylation reaction leading to
the extension of the glycan backbone of peptidoglycan as
well as the transpeptidation reaction leading to the cross-
linking of pentapeptide bridges [17, 18]. This mode of
action confers a slowly bactericidal character to van-
comycin, which is limited to fast-growing organisms [19].
Resistance to vancomycin has emerged over the years and
is mediated by two distinct mechanisms. In S. aureus, a
thickening of the cell wall confers a so-called VISA
(vancomycin-intermediate S. aureus) phenotype, with the
minimum inhibitory concentration (MIC) typically ranging
between 3 and 8 mg/L. This phenotype was first described
in 1997 [20]. The underlying mechanism is not yet fully
elucidated but it has been associated with mutations in the
RNA polymerase gene rpoB and in genes that are directly
or indirectly involved in the biosynthesis/metabolism of the
cell wall, including two-component sensory regulatory
systems (for a recent review, see Gardete and Tomasz
[21]). In enterococci, high-level resistance is mediated by
the occurrence of an alternative pathway for cell wall
synthesis. It results from the acquisition of transposon-en-
coding genes that allow for (a) the hydrolysis of precursors
ending in D-Ala-D-Ala and (b) the synthesis of cell wall
precursors ending in D-Ala-D-Lac or D-Ala-D-Ser and
showing reduced affinity for glycopeptides (see Courvalin
[22] for a review). Very few cases of S. aureus that have
acquired this type of transposon and harbor high-level
resistance to vancomycin [vancomycin-resistant S. aureus
(VRSA)] have been described but they do not seem to
spread so far [23].
3.2 Mechanism of Action of Lipoglycopeptides
Because all lipoglycopeptides keep the aglycone moiety of
conventional molecules in their structure, they also con-
serve this primary mode of action. Yet their specific
chemical features confer to them additional antibacterial
properties. An early work [24] suggested that the interac-
tion between glycopeptides and the D-Ala-D-Ala motif can
be enhanced by two mechanisms, namely (a) the formation
of homodimers between glycopeptide molecules, which
confers a structural rigidity that locks the binding pocket
into the correct conformation and may allow for a coop-
erative binding to the ligand, and (b) the anchoring of the
antibacterial in the membrane, which may help to maintain
the drug close to its target (see Van Bambeke et al. [25] for
a review).
Dimer formation has been shown to occur with orita-
vancin [1, 26] via the additional 4-epi-vancosamine sugar,
putting the molecule in a back-to-back orientation and
allowing cooperative binding to the ligand. Dalbavancin
also strongly dimerizes in solution, and even in the
absence of a ligand [27, 28], but via lipophilic side
chains. However, in this case, both dimer formation and
interaction with cell wall precursors are non-cooperative
(the molecule adopting a ‘closed’ conformation upon
ligand binding) and do not contribute to improve the
antibacterial activity.
Membrane anchoring has been documented for both
oritavancin and telavancin via their lipophilic side chain
linked to the disaccharide moiety [29, 30]. Both molecules
also cause aberrant septum formation and loss of staining
of nascent septal cross walls in electron microscopy, which
may result from their effect on cell wall synthesis and/or
activation of autolysins [31]. Yet oritavancin shows the
unique property of keeping activity against vancomycin-
resistant enterococci (VRE) and staphylococci [32].
For telavancin, a specific, high-affinity interaction with
lipid II has been demonstrated, leading to membrane
depolarization, bacterial lysis, and rapid bactericidal effect
[30, 33]. Microarray analyses revealed that after 15 min of
exposure to the drug a strong expression of the cell wall
stress stimulon (characteristic response to inhibition of cell
wall biosynthesis), which was accompanied after 60 min of
exposure by an induction of various genes, was also
affected by other membrane-depolarizing drugs [34]. These
data support a dual mode of action and may explain the
bimodal shape of concentration–effect relationships in kill-
curve experiments [35].
2076 F. Van Bambeke
Author's personal copy
Oritavancin also disrupts membrane integrity and causes
membrane depolarization both in bacterial cells and lipo-
somes reconstituted from lipids of S. aureus [29, 36].
These effects are also related to the capacity of oritavancin
to specifically bind to lipid II, with additional interaction
sites compared with its precursor chloreremomycin, which
can explain its improved activity on vancomycin-resistant
strains [37]. Solid-state nuclear magnetic resonance (NMR)
studies have indeed shown that oritavancin possesses two
binding sites on the lipid-linked disaccharide–pentapeptide
monomers in S. aureus (D-Ala-D-Ala termini, like van-
comycin, but also the pentaglycyl bridging segment via its
lipophilic side chain on the dissacharide and components of
its aglycon structure). This allows it to inhibit not only
transglycosylase activity, and thus precursor chain exten-
sion, but also transpeptidase activity, and thus precursor
cross-linking [38]. In Enterococcus faecium, inhibition of
transpeptidase becomes even more prominent due to the
preferential interaction of oritavancin with multiple sites on
the peptidic bridge [39]. In this case, interaction with D-
Ala-D-ala termini becomes marginal, explaining why
transglycosylase activity is no longer the primary target of
the drug. More importantly, this also rationalizes why
oritavancin still exerts activity on vancomycin-resistant
strains.
3.3 Spectrum of Activity
Because of their high molecular weight, lipoglycopeptides,
like glycopeptides, cannot cross bacterial membranes and
the cell wall, meaning that their spectrum of activity is
limited to Gram-positive bacteria in which their target is
directly accessible. A large number of studies have
examined the in vitro activity of these compounds against
bacterial membrane
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Fig. 2 Illustration of the late stages of peptidoglycan synthesis
[transglycosylation (in blue) and transpeptidation (in red) reactions]
and of the way vancomycin and oritavancin interact with the lipid II
precursor in order to inhibit these reactions. Vancomycin and new
lipoglycopeptides establish 5 hydrogen bounds with the D-Alanyl-D-
Alanine extremity of the pentapeptidic terminus of lipid II (zone
highlighted in green) [17], which leads, by steric hindrance, to an
inhibition of the glycan chain extension and, to a lesser extent, of
crosslinking between peptidic stems. Oritavancin has additional
interactions with the pentaglycyl bridge and the D-iso-glutamine
residue in position 2 of the pentapeptide terminus of lipid II (zone
highlighted in orange) [37], which allow it to be a stronger inhibitor
of transpeptidases [38]
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collections of Gram-positive clinical isolates, yet many of
these studies were performed using broth that was not
supplemented by polysorbate-80, which is needed to pre-
vent the adsorption of the drugs to the plastic [40–42].
Table 1 therefore focuses on recent studies that have used
the standard procedure currently recommended by the
Clinical Laboratory Standards Institute (CLSI), i.e.,
0.002 % polysorbate-80 added to the culture medium [43].
Against vancomycin-susceptible staphylococci, strepto-
cocci, or enterococci, the three drugs show quite similar
MIC distributions and are more potent than vancomycin.
Yet a clear-cut correlation between the MICs of van-
comycin and of the lipoglycopeptides has been demon-
strated, and thus vancomycin MIC can be used as a
surrogate for susceptibility to lipoglycopeptides [44–46].
Oritavancin is slightly more potent than the other com-
pounds on enterococci. It is also the only one to keep useful
activity against VRE harboring the vanA genotype or
against VRSA [47]. Teicoplanin, dalbavancin, and tela-
vancin remain active on vanB-type resistant strains because
they are not inducers for this specific resistance genotype
[48, 49]. The MICs are 2–4 dilutions higher against VISA
than against MRSA for the three drugs [47, 50, 51].
Like vancomycin, lipoglycopeptides are active on
Clostridia, including C. difficile, with MICs measured in
the absence of polysorbate ranging from 0.125 to 2 mg/L
for oritavancin [52] (1 dilution lower with polysorbate-80
[53]), 0.25 to 0.5 mg/L for telavancin [54], and 0.125 to
0.5 mg/L for dalbavancin [55]. In addition, oritavancin
proved effective against C. difficile infection after 4 days
of treatment in an in vitro model of human gut [56] and
does not induce spore germination or toxin production both
in vitro and in vivo [57, 58].
Resistance to lipoglycopeptides has not yet been
described in clinics; it is less likely to occur for drugs
showing multiple modes of action. In laboratory mutants, a
moderate level of resistance to oritavancin in enterococci
has been ascribed to the complete elimination of precursors
ending in D-Ala-D-Ala during cell wall synthesis, or to the
expression of the accessory gene vanZ, which also confers
resistance to teicoplanin by an unknown mechanism [59].
Mutations in the sensor VanSB of Enterococcus faecalis
can also induce low-level resistance to both teicoplanin and
oritavancin, which are not inducers of the wild-type VanSB
sensor. Transcriptomic studies of a telavancin-resistant
mutant in S. aureus revealed multiple changes in gene
expression, including upregulation of genes involved in
cell wall or fatty acid biosynthesis as well as stress
response, and downregulation of genes included in lysine
biosynthesis, synthesis of surface proteins, modulin or
proteases, and anaerobic metabolism as well as global
regulators such as agr [60]. These changes are accompa-
nied by a thickening of the cell wall and a decrease in the
activity of autolysins, which is reminiscent of what is
observed in VISA strains.
3.4 In Vitro Models of Persistent Infections
Staphylococci, which constitute the primary therapeutic
target for these drugs, may adopt specific lifestyles asso-
ciated with the persistent or recurrent character of infec-
tion, namely growth within biofilm [61] and intracellular
survival [62]. The activity of lipoglycopeptides on these
specific types of infections has thus been investigated in
appropriate models.
Against static biofilms grown on plastic pegs and made of
methicillin-sensitive S. aureus (MSSA), MRSA or VISA,
oritavancin was effective at minimal biofilm eradication
concentrations (MBECs) ranging between 0.5 and 8 mg/L,
which are only 1 dilution higher than the MICs [63]. Tela-
vancin activity has been investigated in a wide range of
biofilmmodels, including in vitro static and dynamicmodels
with MSSA, MRSA, VISA, or even enterococci [64–66] as
well as animal models (see Chan et al. [67] for an indepth
review on this specific topic). Globally speaking, telavancin
proves as, or often more, effective than vancomycin thanks
to its bactericidal character.
Against intracellular bacteria infecting THP-1 cells
(native monocytes or differentiated in macrophages), ori-
tavancin appears to be the most effective of all the
antibacterials tested in this model, reaching a true intra-
cellular bactericidal effect (-3 log10 decrease in bacterial
counts), as demonstrated against intracellular MSSA [68,
69], MRSA, VISA (including strains collected from a
patient with bacteremia) [70], or even small colony vari-
ants [71–73]. It also proved synergistic with other bacte-
ricidal antibacterials such as fluoroquinolones or rifampicin
against small colony variants [74]. This remarkable intra-
cellular activity was attributed to the capacity of orita-
vancin to accumulate within the lysosomes of cells to
exceptionally high levels by a process of adsorptive
endocytosis [75]. Telavancin was also more effective than
vancomycin in THP-1 cells infected by MSSA, MRSA, or
VISA, reaching a bactericidal effect after 3 h; however, its
activity was much slower against VRSA, with a bacteri-
cidal effect being reached only after 24 h of incubation
with concentrations higher than ten times the MIC [35].
Nevertheless, the high accumulation of oritavancin
inside eukaryotic cells raises the question of a potential
toxicity. In vitro studies have indeed demonstrated the
deposition of undigested lipidic material within lysosomes
of cells exposed to the drug continuously for 1–3 days [76],
but only in conditions generating intracellular concentra-
tions well above those measured in macrophages from
patients treated with the drug [77]. Moreover, this effect
was reversible upon drug removal [76]. When the exposure
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Table 1 Minimum inhibitory concentration distributions of new lipoglycopeptides versus vancomycin against clinically relevant pathogensa
Bacterial species Phenotype Number
of strains
New glycopeptides Vancomycin References
Antibacterial Range
(mg/L)
MIC50
(mg/L)
MIC90
(mg/L)
Range
(mg/L)
MIC50
(mg/L)
MIC90
(mg/L)
MSSA (methicillin-
susceptible
Staphylococcus aureus)
All 3245 TLV B0.015
to 0.12
0.03 0.06 [40]
All 1460 ORI B0.004
to 0.25
0.03 0.06 B0.12
to 2
0.5 1 [50]
All 2958 ORI B0.008
to 0.25
0.03 0.06 B0.12
to 2
1 1 [173]
All 514 DAL B0.03 to
0.25
0.06 0.06 B0.12
to 2
1 1 [174]
MRSA (methicillin-resistant
S. aureus)
All 3019 TLV B0.015
to 0.25
0.03 0.06 0.25 to
4
1 1 [40]
All 427 ORI B0.004
to 0.25
0.03 0.06 0.5 to
2
1 1 [50]
All 3376 ORI B0.008
to 0.25
0.03 0.06 0.25 to
2
1 1 [173]
All 522 DAL B0.03 to
0.12
0.06 0.06 0.5 to
2
1 1 [174]
All 61,195 DAL B0.008
to 0.25
0.06 0.06 B0.12
to 4
1 1 [175]
VAN
MIC C2
115 TLV B0.015
to 0.12
0.06 0.06 [40]
VAN
MIC C2
124 ORI 0.015 to
0.25
0.06 0.06 [173]
Staphylococcus epidermidis All 221 ORI 0.008 to
0.5
0.06 0.12 B0.12
to 2
1 2 [50]
Coagulase-negative
staphylococci (CONS)
All 461 TLV B0.015
to 0.12
0.06 0.06 0.5 to
4
1 2 [40]
All 115 DAL B0.03 to
0.25
B0.03 0.06 0.25 to
2
1 2 [174]
Enterococcus faecalis All 304 ORI B0.004
to 0.5
0.03 0.06 0.25 to
4
1 2 [50]
VAN-S 325 TLV B0.015
to 0.25
0.12 0.12 0.5 to
4
1 1 [40]
VAN-S 1320 ORI B0.008
to 0.25
0.015 0.03 0.25 to
4
1 2 [173]
VanA 45 ORI 0.03-1 0.25 0.5 [16 [16 [16 [173]
VanB 19 ORI B0.008
to 0.06
0.015 0.03 8 to
[16
[16 [16 [173]
Enterococcus faecium VAN-S 81 TLV B0.015
to 0.12
0.03 0.06 0.25 to
4
1 1 [40]
VAN-S 87 ORI B0.004
to 0.03
0.008 0.015 0.25 to
2
0.5 1 [50]
VAN-S 177 ORI B0.008
to 0.03
B0.008 B0.008 0.25 to
4
1 1 [173]
VanA 241 TLV B0.015
to[2
1 2 [16 [16 [16 [40]
VanA 22 ORI B0.004
to 0.5
0.008 0.12 32 to
[32
[32 [32 [50]
VanA 600 ORI B0.008
to 0.5
0.03 0.12 [16 [16 [16 [173]
VanB 16 ORI B0.008
to 0.03
B0.008 B0.008 8 to
[16
[16 [16 [173]
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of cells was limited to drug amounts for which cellular
concentrations were of the same order of magnitude as
those measured in patients, no specific sign of intoxication
of macrophages was evidenced, including with respect to
phagocytic or killing capacities or oxidant species pro-
duction [77, 78]. Telavancin also caused cellular lipidosis,
but to a much lower extent than oritavancin, related to its
lower cellular accumulation [79].
4 Pharmacokinetics and Pharmacodynamics
4.1 In Vitro Pharmacodynamics
Oritavancin shows bactericidal activity which is rapid (1 h)
against Streptococcus pyogenes, MRSA, and VRSA,
slower (10–20 h) against daptomycin-resistant S. aureus,
and VRE and vancomycin-susceptible enterococci (VSE),
or even slower (24 h) against VISA in in vitro models of
continuous exposure to the drug [80–82]. It was also
rapidly (1 h) bactericidal against Streptococcus pneumo-
niae in an in vitro pharmacodynamic model [83]. More-
over, it remains bactericidal against high inocula of
vancomycin-susceptible S. aureus as well as against het-
ero-VISA (h-VISA), but not against VISA at a concentra-
tion mimicking the free maximum concentration (Cmax)
reached in the serum of patients after a single dose of
1200 mg [84, 85].
Telavancin also proved more rapidly bactericidal against
MSSA, MRSA, and h-VISA than against VISA, VRSA, or
coagulase-negative S. aureus [35, 86]. It remains bacteri-
cidal against h-VISA at high inoculum but after a longer
Table 1 continued
Bacterial species Phenotype Number
of strains
New glycopeptides Vancomycin References
Antibacterial Range
(mg/L)
MIC50
(mg/L)
MIC90
(mg/L)
Range
(mg/L)
MIC50
(mg/L)
MIC90
(mg/L)
Enterococcus spp. VAN-S 30 DAL B0.03 to
0.12
B0.03 0.06 0.5 to
2
1 1 [174]
VanA 24 DAL 0.24 to
[4
4 4 [16 [16 [16 [174]
VanB 2 DAL B0.03 B0.03 [16 [16 [174]
Streptococcus pneumoniae All 1801 TLV B0.015
to 0.06
B0.015 B0.015 B0.12
to 2
1 1 [40]
Peni-S 216 ORI B0.008
to 0.12
B0.008 0.03 [173]
Peni-R 86 ORI B0.008
to 0.25
0.015 0.06 [173]
Viridans group streptococci
(VGS)
All 446 TLV B0.015
to 0.06
B0.015 B0.015 B0.12
to 1
0.5 1 [40]
All 40 DAL B0.03 to
0.12
B0.03 0.06 0.25 to
1
0.5 1 [174]
Peni-S 216 ORI B0.008
to 0.12
B0.008 0.03 [173]
Peni-R 86 ORI B0.008
to 0.25
0.015 0.06 [173]
Streptococcus pyogenes All 449 TLV B0.015
to 0.12
B0.015 0.03 [40]
All 132 ORI B0.0005
to 0.5
0.03 0.25 0.25 to
1
0.5 0.5 [50]
All 155 DAL B0.03 to
0.12
B0.03 B0.03 0.25 to
0.5
0.25 0.5 [174]
Streptococcus agalactiae All 393 TLV B0.015
to 0.12
0.03 0.06 [40]
All 153 DAL B0.03 to
0.25
B0.03 0.12 0.25 to
1
0.5 0.5 [174]
DAL dalbavancin, MIC minimum inhibitory concentration, MIC50 MIC at which 50 % of bacteria are inhibited, MIC90 MIC at which 90 % of
bacteria are inhibited, ORI oritavancin, Peni-R penicillin-resistant, Peni-S penicillin susceptible, TLV telavancin, VAN vancomycin, VanA VanA
phenotype of vancomycin resistance, VanB VanB phenotype of vancomycin resistance, VAN-S vancomycin susceptible
a Limited to studies published from 2012 and July 2015, where lipoglycopeptides where tested in the presence of 0.002 % polysorbate-80 and
compared to VAN
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incubation time (16 h) [87]. In an in vitro pharmacody-
namic model mimicking human exposure to 10 mg/kg,
telavancin was bactericidal after 8 h against h-VISA,
linezolid-resistant S. aureus, and daptomycin-resistant
S. aureus, but was bactericidal after 24 h against VISA
[88]. In contrast, telavancin is bacteriostatic on C. difficile
[54].
In sharp contrast, dalbavancin is slowly bactericidal
against S. aureus and S. pyogenes, a 24-h incubation being
needed to observe bacterial eradication [89].
Synergy has been demonstrated in vitro between orita-
vancin and aminoglycosides, b-lactams, linezolid, or
rifampin against MRSA or enterococci [90–93] as well as
between telavancin and b-lactams, aminoglycosides, or
rifampin against MRSA [94, 95], or dalbavancin and
oxacillin against MRSA [96].
4.2 Animal Pharmacodynamic Models
Ambrose and coworkers have reviewed the activity of
oritavancin in animal models [97]. Oritavancin is as or
more effective than comparators (vancomycin, dapto-
mycin) for the treatment of MRSA or Enterococcus
endocarditis, while at the same time better in preventing
relapses [98, 99]. It is also very effective for the treatment
of MRSA pneumonia or bacteremia. It is more active than
vancomycin against C. difficile infection by the oral route
in the hamster model and prevents spore germination [57,
58]. A high single dose reduced bacterial burden in a
catheter infection by VanA enterococci [100] as well as in
pneumonia or in meningitis caused by pneumococci [101,
102]. A single dose is also protective against anthrax in a
murine model of spore inhalation [103].
Telavancin activity in animals has also been recently
reviewed [104]. In brief, its efficacy and superiority com-
pared with vancomycin or daptomycin has been docu-
mented in murine models of bacteremia or pneumonia by
MRSA [105, 106], in murine subcutaneous infection
models, in rabbit endocarditis caused by MRSA, VISA, or
daptomycin non-susceptible staphylococci [107–109], as
well as in rabbit meningitis caused by penicillin-resistant
pneumococcus [110, 111]. It was equivalent to vancomycin
or linezolid in a model of rabbit osteomyelitis caused by
MRSA [112].
With respect to dalbavancin, it showed activity in a rat
granuloma pouch infection model by MSSA and MRSA
[113], in neutropenic murine thigh and lung infection
models by S. aureus or S. pneumoniae [114], in rabbit
endocarditis caused by S. aureus, including strains with
reduced susceptibility to glycopeptides [115], in foreign
body infection by MRSA in guinea pigs [116], and in an
anthrax inhalation model [117].
4.3 Pharmacokinetics/Pharmacodynamics
for Dosing Optimization
In neutropenic mice thigh infection models aimed at
determining pharmacokinetic/pharmacodynamic (PK/PD)
parameters predictive of efficacy, free area under the
concentration–time curve (AUC)/MIC is the best predictor
of efficacy for the three drugs, together with the Cmax/MIC
ratio for oritavancin, based on its highly bactericidal
character [104, 114, 118, 119].
For oritavancin, its concentration-dependent bactericidal
activity combined with its prolonged half-life (see Sects.
4.1 and 4.4) has led to the selection of a 1200 mg single-
dose treatment [97], which allows maximization of the
Cmax/MIC and AUC/MIC ratio while at the same time
facilitating drug administration. In population pharma-
cokinetic studies of patients treated with this dose, the Cmax
reaches 138 mg/L (20.7 mg/L for free fraction) and the
AUC reaches 1110 mgh/L (165 for free fraction) after
24 h and 2510 mgh/L after 576 h [120]. If considering the
PK/PD breakpoint of 0.125 mg/L established by both
European Committee on Antimicrobial Susceptibility
Testing (EUCAST) and FDA for S. aureus (Table 2), the
fCmax/MIC and fAUC24/MIC are as high as 165 and
1352 h, respectively, after administration of 1200 mg to
humans. Simulating this dose in an in vitro pharmacody-
namic model of infection by MRSA generated considerable
bactericidal effect [121].
For telavancin, an AUC24/MIC ratio of 219 h has been
proposed as the PK/PD target associated with a 1 log10
CFU (colony-forming units) decrease in models of
infection by MRSA in neutropenic mice. This value
could be achieved in patients with normal renal function
receiving a daily dose of 10 mg/kg for MICs B2 mg/L
[122]. It was nevertheless challenged based on incon-
sistencies in the reported MIC values for the MRSA
strain used for this study [123]. Accordingly, a lower
susceptibility breakpoint of 1 mg/L had first been selec-
ted by the FDA, allowing a target AUC/MIC of 438 to
be reached. Yet this breakpoint has recently been revised
by both the FDA and the EUCAST to a value of
0.125 mg/L based on the new procedure established by
CLSI for determining the MIC in the presence of
polysorbate-80 (see Table 2).
For dalbavancin, Monte-Carlo simulations combining
pharmacokinetic and MIC data from phase III trials sug-
gest a PK/PD breakpoint of 1 mg/L for staphylococci,
allowing a fAUC14days/MIC[1000 h to be reached [114,
124], but, again, these were based on MICs determined in
the absence of polysorbate-80. The current susceptibility
breakpoint is therefore much lower (0.12 mg/L; see
Table 2).
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4.4 Human Pharmacokinetics and Dosing
The pharmacokinetic profile of the three drugs after
administration of registered doses to humans is illustrated
in Table 3. As compared with vancomycin, the main
characteristic of these drugs is their long half-life, which is
related to their high protein binding but also to their
capacity to accumulate within eukaryotic cells. The half-
life is particularly prolonged (longer than 200 h) for ori-
tavancin and dalbavancin, justifying their administration
schedules (single or two doses, respectively). Remarkably,
oritavancin shows a distribution volume of 87 L and
reaches concentrations in alveolar macrophages as high as
142-fold its serum concentration. Dalbavancin reaches
concentrations of 6.3 and 4.1 lg/g in articular tissues 12 h
and 4 weeks, respectively, after the administration of
1000 mg. Subsequent administrations of 500 mg per week
for 7 weeks did not cause drug accumulation and was well-
tolerated, warranting investigation into interest in the use
of this drug for the treatment of osteomyelitis [125].
While oritavancin does not require any dose adaptation
in cases of impaired renal function, both telavancin and
dalbavancin do need an adjustment. In patients with hep-
atic insufficiency, no dose adjustment is recommended for
oritavancin [6, 120] or telavancin [10, 126] for Child-Pugh
grades A–B, or for dalbavancin for Child-Pugh grade A [6,
10, 14]. Caution should be exercised in case of more severe
dysfunction, as no specific data are available. These drugs
cannot be administered to pregnant (class C) or breast-
feeding women, or to children. However, a recent phase I,
open-label study conducted with dalbavancin on children
from 12 to 17 years old concluded that similar plasma
exposures were obtained after administration of 1000 mg
or 15 mg/kg, with acceptable tolerance [127]. AUC expo-
sures were, however, 30 % lower than in adults who
received the same dose, which is consistent with enhanced
renal and/or hepatic elimination in healthy adolescents.
Other open-label studies focusing on the pharmacokinetics
and safety of oritavancin (NCT02134301 [128]) and tela-
vancin (NCT02013141 [129]) in patients younger than 18
or 17 years, respectively, are ongoing.
5 Clinical Efficacy
5.1 Registered Indications
Table 4 shows the main clinical trials that led to the reg-
istration of lipoglycopeptides for the treatment of acute
bacterial skin and skin structure infections and for hospital-
acquired pneumonia (telavancin only). The reader is
referred to recent reviews that have examined these studies
in details (oritavancin [32, 130], telavancin [131, 132], and
dalbavancin [133, 134]).
Globally speaking, and focusing on acute bacterial skin
and skin structure infections (a common indication for the
three drugs), phase II and III trials concluded that the
investigated drug was non-inferior to conventional therapy
[vancomycin IV, anti-staphylococcal penicillin, linezolid
(with possible oral switch)]. The safety profile was also
globally comparable to that of the comparators. A post hoc
analysis was recently published for telavancin, in which
data from the ATLAS [Assessment of Telavancin in cSSSI
(complicated skin and skin structure infection)] trials were
reanalyzed taking into consideration the recent guidance
from the FDA concerning studies evaluating antibacterials
Table 2 Current susceptibility
breakpoints for new
lipoglycopeptides as compared
with vancomycin
Antibacterial Bacterial species US FDA EUCAST
SB RC SB R[
Vancomycin Coagulase-negative staphylococci (CONS) 4 32 4 4
Streptococci (other than pneumoniae) 1 NA 2 2
Enterococci 4 32 4 4
Other staphylococcal or streptococcal species 2 16 2 2
Oritavancin Staphylococci 0.12 NA 0.125 0.125
Streptococci 0.25 NA 0.25 0.25
Enterococcus faecalis 0.12 NA 0.125 0.125
Telavancin Staphylococci 0.12 NA 0.125 0.125
Streptococci 0.12 NA
E. faecalis 0.25 NA
Dalbavancin Staphylococci 0.12 NA 0.125 0.125
Streptococci 0.12 NA
EUCAST European Committee on Antimicrobial Susceptibility Testing, FDA Food and Drug Adminis-
tration, NA not applicable (no resistant isolate described so far), R resistant, S susceptible
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for acute bacterial skin and skin structure infections that
was issued after the performance of these trials (namely,
inclusion of patients with lesion size C75 cm2 and exclu-
sion of patients with ulcers or burns) [135]. The adoption of
an updated test-of-cure clinical response (C90 % reduction
in lesion size, no increase in lesion size since day 3, and no
requirement for additional antibacterialcs/significant sur-
gical procedures) concluded that there was equivalence
between telavancin- and vancomycin-treated patients (68.0
vs. 63.3 % cure rates).
Phase II studies determined the optimal dosing regimen
as being a single dose of 1200 mg for oritavancin (SIM-
PLIFI trial [3]), a 1000 mg dose at day 1 followed by a
500 mg dose at day 7 for dalbavancin [136], and a 10 mg/
kg daily dose for telavancin (FAST 2 trial [137]). Thus, a
possible advantage of oritavancin and dalbavancin resides
in their simplified therapeutic scheme, which may even
allow their use for home therapy [138, 139].
Telavancin is also indicated for HABP and VABP
caused by susceptible isolates of S. aureus (including
methicillin-susceptible and -resistant isolates), based on
the ATTAIN (Assessment of Telavancin for Treatment of
Hospital-Acquired Pneumonia) phase III trials, which
showed non-inferiority to vancomycin for this indication
[140]. A secondary objective of the ATTAIN trials was to
perform a pooled analysis of the two studies with respect
to telavancin superiority compared with vancomycin in
patients with pneumonia attributable to MRSA [140]. The
clinical response between the two groups was similar, but
cure rates were higher in the telavancin group when
considering patients with mono-microbial infection due to
S. aureus (both MRSA and MSSA; 84.2 vs. 74.3 % suc-
cess rate for telavancin and vancomycin, respectively) or
patients infected with strains showing a vancomycin MIC
[1 mg/L (87.2 vs. 74.3 % success rate for telavancin and
vancomycin, respectively). In contrast, lower cure rates
were observed in the telavancin-treated group for patients
with mixed infections (66.2 vs. 79.4 % success rate for
telavancin and vancomycin, respectively); the difference
disappeared if patients who received adequate Gram-
negative coverage were considered (66.3 vs. 66.7 %
success rate for telavancin and vancomycin, respectively)
[141]. Of note, the clinical success of telavancin was also
lower than that of vancomycin in the subgroup of patients
with severe renal impairment (creatinine clearance
\30 mL/min) or pre-existing acute renal failure, including
Table 3 Pharmacokinetics and dosing of new lipoglycopeptides
Parameter Antibacterial
Oritavancin Telavancina Dalbavancinb
Dosing
Creatinine clearance[50 mL/min 1200 mg single dose; 3 h infusion [6] 10 mg/kg q24h [10] 1000 mg day 1 ? 500 mg day 7 [14]
Creatinine clearance 30–50 mL/min 1200 mg single dose; 3 h infusion [6] 7.5 mg/kg q24h [10] 1000 mg day 1 ? 500 mg day 7 [14]
Creatinine clearance 10–\30 mL/min 1200 mg single dose; 3 h infusion [6] 10 mg/kg q48h [10] 750 mg day 1 ? 375 mg day 7 [14]
Cmax (mg/L) 138 [6] 94/108 [10] 287 [14]
AUC24 (mgh/L) 1110 [6] 666/780 [10] 3185 [14]
AUC? (mgh/L) 2800 [6] 747/NA [10] 23,443 [14]
Protein binding (%) 85 [6] 90 [10] 93 [14]
ta (h) 2.29 [6] 8/8.1 [10] NA
tb (h) 13.4 [6] NA
tc (h) 245 [6] 346 [14]
Clearance (L/h) 0.445 [6] 0.97/0.90 [10] 0.015 [14]
Vss (L) 87.6 [6] 10.15/9.31 [10] 7.93 [176]
Macrophages/plasma 142.7c [177] 6.67 (24 h) [178] NA
ELF/serum 4.6c [177] 0.7 [179] NA
AUC? area under the concentration–time curve from time zero to infinity, AUC24 area under the concentration–time curve from time zero to
24 h, Cmax maximum concentration, ELF epithelial lining fluid, NA not available, qxh every x h, ta initial or disposition half-life, tb terminal
elimination half-life in a 2-compartment model, tc terminal elimination half-life in a 3-compartment model, Vss apparent volume of distribution
at steady state
a Pharmacokinetic data given for single dose/multiple dose of 10 mg/kg
b Pharmacokinetic data for a single dose of 1000 mg
c For an 800 mg dose
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Table 4 Main clinical trials involving new lipoglycopeptides for their current indications
Phase Study name and/or
ClinicalTrials.gov
identifier
Study arm (number
of patients; ITT)
Comparator
(number of
patients; ITT)
Indications Outcomes References
II SIMPLIFI
NCT00514527
ORI 1200 mg
day 1 (99)
ORI 800 mg day 1
[?400 mg day 5]
(100)
ORI 200 mg/day
for 3–7 days
(103)
Acute bacterial skin and
skin structure infections
(wound infections,
major abscess, and
cellulitis)
Non-inferiority (15 %
margin):
• Clinical response at
days 21–29
[3]
III SOLO 1
NCT01252719
ORI 1200 mg
day 1 (475)
VAN 1 g or 15 mg/
kg bid 7–10 days
(479)
Acute bacterial skin and
skin structure infections
(wound infections,
major abscess, and
cellulitis)
Non-inferiority (10 %
margin):
- No spreading or
reduction of lesion size
measured at 48–72 h,
absence of fever, and no
need for rescue
antibacterials
- Clinical cure within
7–14 days
- C20 % reduction in
lesion size at 48–72 h
[159]
III SOLO 2
NCT01252732
ORI 1200 mg
day 1 (503)
VAN 1 g or 15 mg/
kg bid 7–10 days
(502)
Acute bacterial skin and
skin structure infections
(wound infections,
major abscess, and
cellulitis)
Non-inferiority (10 %
margin):
- No spreading or
reduction of lesion size
measured at 48–72 h,
absence of fever, and no
need for rescue
antibacterials
- Clinical cure within
7–14 days
- C20 % reduction in
lesion size at 48–72 h
[158]
II FAST 1 TLV 7.5 mg/kg
q24h (84)
Antistaphylococcal
penicillin 2 g q6h
or VAN 1 g q12h
(85)
Complicated skin and
skin structure infections
(major abscess
requiring surgical
drainage; deep,
extensive cellulitis;
infected wound or
ulcer; infected burn)
Non-inferiority:
• Clinical evaluation at
EOT and TOC (7–14
days after end of
therapy) visits
[180]
II FAST 2 TLV 10 mg/kg
q24h (103)
Antistaphylococcal
penicillin 2 g q6h
or VAN 1 g q12h
(98)
Complicated skin and
skin structure infections
(major abscess
requiring surgical
drainage; deep,
extensive cellulitis;
infected wound or
ulcer; infected burn)
Non-inferiority:
• Clinical evaluation at
EOT and TOC
(7–14 days after end of
therapy) visits
[137]
III ATLAS 1 and 2
NCT00091819
NCT00107978
TLV 10 mg/kg
q24h for
7–14 days (928)
VAN 1 g q12h for
7–14 days (939)
Complicated skin and
skin structure infections
(major abscess
requiring surgical
drainage; deep,
extensive cellulitis;
infected wound or
ulcer; infected burn)
Non-inferiority (10 %
margin):
• Clinical evaluation at
TOC (7–14 days after
end of therapy) visits
[156]
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those on hemodialysis [142], but was equivalent for both
drugs when excluding these subgroups from the analysis
[143]. In Europe, telavancin is therefore not recom-
mended for the treatment of hospital-acquired pneumonia
in these circumstances [11].
5.2 Other Types of Infections
The usefulness of these drugs in other potential indications
has been examined in small series of patients or even in
case reports.
Table 4 continued
Phase Study name and/or
ClinicalTrials.gov
identifier
Study arm (number
of patients; ITT)
Comparator
(number of
patients; ITT)
Indications Outcomes References
III ATTAIN 1 and 2
NCT00107952
NCT00124020
TLV 10 mg/kg
q24h for
7–21 days (749)
VAN 1 g q12h for
7–21 days (754)
Pneumonia acquired after
48 h in an inpatient
acute or chronic care
facility or that
developed within
7 days after being
discharged
Non-inferiority (20 %
margin):
Improvement or lack of
progression of baseline
radiographic findings at
end of EOT and
resolution of signs and
symptoms of
pneumonia at TOC visit
Superiority compared
with vancomycin
treatment in patients
with pneumonia due to
MRSA (not met)
[140]
II
(open-
label)
None DAL 1 g day
1 ? 500 mg
day 7 (20)
DAL 1100 mg
day 1 (20) or
standard of care
(21)
Complicated skin and
skin structure infections
(major abscess, infected
ulcer, a major burn
deep and extensive
cellulitis)
Clinical response at the
TOC visit (day 24 for
1-dose DAL, day 34 for
2-dose DAL, and
2 weeks after the last
dose for comparators)
[136]
III None DAL 1 g
day 1 ? 500 mg
day 7 (571)
LZD 600 mg bid
(iv or po) for
14 days (283)
Complicated skin and
skin structure infections
(major abscesses, major
burns, traumatic or
surgical wound
infections, and deep
skin/skin-structure
infection) or known or
suspected to be caused
by MRSA
Non-inferiority (12.5 %
margin):
• Evaluation of clinical
and microbiological
responses, both
separately and
combined, at the EOT
and TOC visits
[181]
III DISCOVER 1
NCT01339091
DAL 1 g day
1 ? 500 mg
day 7 (288)
VAN 1 g or 15 mg/
kg bid for 3 days
with possible
switch to oral
LZD 600 mg bid
up to 10–14 days
(285)
Acute bacterial skin and
skin structure infections
(wound infections,
major abscess, and
cellulitis)
Non-inferiority (10 %
margin):
• Early clinical response
at 48–72 h: cessation of
spread of the erythema
associated with the
infection; temperature
B37.6 C
[182]
III DISCOVER 2
NCT01431339
DAL 1 g day
1 ? 500 mg day
7 (371)
VAN 1 g or 15 mg/
kg bid for 3 days
with possible
switch to oral
LZD 600 mg bid
up to 10–14 days
(368)
Acute bacterial skin and
skin structure infections
(wound infections,
major abscess, and
cellulitis)
Non-inferiority (10 %
margin):
• Early clinical response
at 48–72 h: cessation of
spread of the erythema
associated with the
infection; temperature
B37.6 C
[182]
bid twice daily, DAL dalbavancin, DISCOVER dalbavancin for infections of the skin compared to vancomycin at an early response, EOT end of
therapy, ITT intent-to-treat, iv intravenous, LZD linezolid,MRSA methicillin-resistant Staphylococcus aureus, ORI oritavancin, po oral, qxh every
x h, TLV telavancin, TOC test of cure, VAN vancomycin
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5.2.1 Oritavancin
The pharmacokinetics and pharmacodynamics of orita-
vancin were evaluated in 55 patients with S. aureus bac-
teremia for both microbiological and clinical responses
[144]. Bayesian oritavancin exposure predictions were
derived using a validated population pharmacokinetic
model for treatments with 5–10 mg/kg of body weight/day;
they identified a breakpoint of the percentage of the dosing
interval duration for which free-drug concentrations were
above the MIC (free-drug % time[MIC) of 22 % for both
microbiological and clinical response. Although of interest,
this study was performed before the new therapeutic
scheme of oritavancin (single dose) was established, lim-
iting its applicability.
5.2.2 Telavancin
Telavancin (10 mg/kg every 24 h, adapted to renal func-
tion; see Table 3) was compared with vancomycin or an
anti-staphylococcal penicillin in a phase II trial for the
treatment of uncomplicated bacteremia, half of the cases of
which were related to catheter infections [ASSURE
(Telavancin for Treatment of Uncomplicated S. aureus
Bacteremia) trial] [145]. Of the 60 enrolled patients, only
eight (telavancin arm) and nine (comparator arm) were
clinically evaluable because they had to fulfill a series of
criteria after the administration of the first dose to continue
the treatment in order to ensure the non-complicated
character of the infection. Comparable cure rates were
recorded in the two arms (88 and 89 %), warranting further
studies in this indication. Of note, among patients infected
by Gram-positive pathogens only enrolled in the two
ATTAIN trials, cure rates for the subgroup of bacteremic
patients was similar in both treatment groups (41 % for
telavancin vs. 40 % for vancomycin), with identical mor-
tality rates [146].
A few case reports have illustrated the efficacy of tela-
vancin in other specific indications. In a patient with
endocarditis, linezolid (microbiologically effective but
thrombocytopenia developed during the 26 days of treat-
ment) was successfully replaced with telavancin (10 mg/
kg/day), with no safety concern after 3 weeks of treatment
[147]. The status of another patient who presented with a
pacemaker lead infection caused by VISA worsened after
successive treatment with vancomycin and daptomycin
(8 mg/kg, increased to 10 mg/kg) but she rapidly became
non-bacteremic once daptomycin had been replaced with
telavancin, with complete cure achieved after 8 weeks of
therapy [148]. Following 2 weeks of unsuccessful therapy
with a combination of vancomycin and oral rifampicin in a
patient with methicillin-resistant S. epidermidis prosthetic
joint infection following bilateral total knee replacement,
the infection was cured with telavancin 10 mg/kg for
6 weeks combined with oral rifampicin [149]. Three
patients with osteomyelitis who did not respond to van-
comycin therapy were successfully treated with telavancin
for 6–10 weeks, with no evidence of recurrence after sev-
eral months [150]. A fourth patient showed an improved
clinical status after 4 weeks of treatment, but his serum
creatinine also rose, which justified a switch to tigecycline
therapy [150]. Likewise, an 18-year-old male with spina
bifida who had chronic osteomyelitis received antibio-
therapy with multiple antimicrobials during 133 days. Cure
and absence of recurrence were eventually achieved with a
regimen consisting of telavancin 750 mg/day for 42 days,
meropenem for 50 days, and oral rifampin for 50 days
[151].
5.2.3 Dalbavancin
A phase II study compared dalbavancin (n = 33; 1000 mg
loading dose on day 1 and 500 mg on day 8) with van-
comycin (n = 34; 1000 mg every 12 h) for the treatment
of catheter-related bloodstream infections [152] and con-
cluded that dalbavancin was superior (clinical success rate:
87 vs. 50 %; microbiological success rate: 95.7 vs.
78.6 %). In both arms, success was higher when catheters
were removed. Dalbavancin also proved effective for the
treatment of catheter-related septic phlebitis caused by
MSSA in a single patient eligible for outpatient therapy
[153].
6 Safety
6.1 Adverse Events
Safety data with lipoglycopeptides are limited to those of
published clinical trials and therefore only concern a few
hundred patients. Thus, rare adverse effects may have
escaped this analysis and could appear after broad-scale
use in real-life patient populations. Therefore, based on the
currently available literature, the safety profile of these
drugs was globally comparable with that of their com-
parators in published trials (see Table 5). A few adverse
events do, however, need to be highlighted and discussed
in more detail.
All three drugs can induce hypersensitivity reactions,
with cross-allergy possible with vancomycin. Thus, their
use should be considered with caution in patients with a
history of allergy to vancomycin and the infusion time
should be at least 1 h to avoid red-man syndrome like
reactions [131].
The risk of corrected QT (QTc) interval prolongation
related to these drugs has been systematically examined in
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Table 5 Adverse drug reactions (in % of patients) for new lipoglycopeptides as presented in the product information (compiled from clinical
trials in patients with acute bacterial skin and skin structure infections [6, 10, 14])a
Adverse reactions Oritavancin
(n = 976)
Vancomycin
(n = 983)
Telavancin
(n = 929)
Vancomycin
(n = 938)
Dalbavancin
(n = 1778)
Vancomycin
(n = 1224)
Body as a whole
Rigors 4 2
Gastrointestinal disorders
Diarrhea 3.7 3.4 7 8 4.4 5.9
Nausea 9.9 10.5 27 15 5.5 6.4
Vomiting 4.6 4.7 14 7 2.8 3.0
Others: gastrointestinal hemorrhage, melena,
hematochezia, abdominal pain
\2
Nervous system disorders
Dizziness 2.7 2.6 6 6
Headache 7.1 6.7
Taste disturbance 33 7
General disorders and administration
Infusion-related reaction \2
Infusion-site phlebitis 2.5 1.5
Infusion-site reaction 1.9 3.5 4 4
Others: infusion-site erythema, extravasation,
induration, edema peripheral
\1
Immune system disorders
Hypersensitivity \1
Musculoskeletal and connective tissue disorders
Tenosynovitis \1
Myalgia \1
Skin and subcutaneous tissue disorders
Pruritis \1 6 13 2.1 3.3
Rash \1 2.7 2.4
Others: urticaria, angioedema, erythema
multiforme, leukocytoclastic vasculitis
\1
Infections and infestations
Abscess (limb and subcutaneous) 3.8 2.3
Osteomyelitis \1
Respiratory, thoracic, and mediastinal disorders
Bronchospasm, wheezing \1
Metabolism and nutrition disorders
Hypoglycemia \1
Decreased appetite 3 2
Renal system
Foamy urine 13 3
Renal impairment 3 1
Hepatobiliary disorders
Hepatotoxicity \2
Blood and lymphatic system disorders
Anemia \1 \2
Eosinophilia \1 \2
Others: hemorrhagic anemia, leucopenia,
neutropenia, thrombocytopenia, thrombocytosis,
petechiae
\2
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healthy volunteers, with negative results reported for ori-
tavancin 800 mg [4] or 1.3-fold the clinical dose of
1200 mg [6], telavancin 7.5–15 mg/kg [154], and dalba-
vancin 1500 mg [155]. In patients from phase III trials,
however, 1.5 % of those patients treated with telavancin
for skin infections (vs. 0.6 % of vancomycin-treated
patients) and 8 % of those treated for pneumonia (vs. 7 %
with vancomycin) experienced QTc interval prolongation
of [60 ms or a QTc interval [500 ms, the risk being
higher when coadministered with drugs known to prolong
the QTc interval or to induce torsades de pointes [10, 140,
156].
For oritavancin, two adverse reactions were more fre-
quent than in the comparator-treated population [157]. First,
oritavancin-treated patients were at higher risk of developing
osteomyelitis (five cases vs. zero for vancomycin in the
SOLO 2 study [158]). These events occurred within
1–9 days after study drug initiation, suggesting that the
osteomyelitis may have been pre-existing at the time of
study entry. Likewise, elevation of transaminases was more
frequent in oritavancin-treated patients in SOLO 1, but it
was transient and not reported as serious or as being asso-
ciated with adverse symptoms related to liver function [159].
Reversible elevation in serum levels of hepatic enzymes was
also reported for dalbavancin, especially in patients with
underlying conditions affecting liver enzymes such as
chronic viral hepatitis of alcohol abuse [14].
With respect to telavancin, two other adverse events of
potential concern were evidenced in clinical trials. First,
telavancin induces taste disturbance, described as a soapy
or metallic taste, in one-third of patients [131]. Second,
signs of renal toxicity have been evidenced such as an
increase in serum creatinine and foamy urine. However, the
latter effect does not necessarily reflect toxicity and could
also possibly be due to the renal elimination of hydrox-
ypropyl-b-cyclodextrin present in the formulation as a
solubilizing agent [160]. Telavancin should thus be used
with caution in patients predisposed to kidney dysfunction
(pre-existing renal disease, diabetes mellitus, congestive
heart failure, or hypertension) [10]. Studies in rats suggest
that the onset of kidney injury depends on the dose and on
the dosing interval (more rapid if a longer dosing interval)
[161].
Elevation of hepatic enzymes was more frequently
noticed in patients receiving dalbavancin than vancomycin
[14]; other adverse effects were comparable.
6.2 Interference with Laboratory Tests and Drug–
Drug Interactions
Oritavancin [6] and telavancin [162] may interfere in
coagulation testing [aPTT (activated partial thromboplastin
time) during 48 h or INR (international normalized ratio)
during 24 h] because of their capacity to inhibit the activity
of phospholipases included in reagents. An anticoagulant
that does not need monitoring may therefore be preferable
during antibacterial therapy. This effect has not been
reported for dalbavancin [14]. Telavancin also interferes
with urine qualitative dipstick protein assays, as well as
quantitative dye methods [10].
Studies of interactions with hepatic cytochromes have
been conducted. Oritavancin appears to be a weak inhibitor
of cytochrome P450 (CYP) 2C9 and 2C19 and a weak
inducer of CYP3A4 and 2D6 [6]. A significant risk of
bleeding has been reported in patients taking warfarin at
the same time. No significant metabolism by hepatic
cytochromes or drug interactions related to inhibition or
induction of metabolism has been described for both tela-
vancin and dalbavancin [10, 14, 163]. Nor was any phar-
macokinetic interaction described when co-administering
telavancin with different b-lactam antibacterials [164].
7 Healthcare Costs
As vancomycin is now a generic drug, the drug acquisition
cost will obviously be much higher with these novel lipo-
glycopeptides (see Table 6). However, the cost of MRSA
Table 5 continued
Adverse reactions Oritavancin
(n = 976)
Vancomycin
(n = 983)
Telavancin
(n = 929)
Vancomycin
(n = 938)
Dalbavancin
(n = 1778)
Vancomycin
(n = 1224)
Alanine aminotransferase increased 2.8 1.5 0.8 0.2
Aspartate aminotransferase increased 1.8 1.5
Total bilirubin increased \1
Hyperuricemia \1
Increase in serum creatinine (1.5-fold) 15 7
Cardiac disorders
Tachycardia 2.5 1.1
a Vancomycin data are presented on the right of each new glycopeptide for the corresponding trial
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infections is only marginally dependent on the price of the
administered drug and mainly reflects the healthcare
resources needed to treat the infections, more specifically
the length of stay in the hospital, which is in general 1.5–3
times greater than for an MSSA infection [165]. When
using the reference drug vancomycin, costs associated with
therapeutic monitoring, twice-daily injection or continuous
infusion, and prolonged treatment duration need to be taken
into account. A cost-effectiveness analysis with telavancin
concluded that the treatment cost would be similar for
patients from the ATLAS studies treated with vancomycin
and telavancin if the acquisition cost of telavancin was
approximately 15 times higher than that of vancomycin;
the cost effectiveness of telavancin was greater if consid-
ering MRSA-infected patients only [166]. The simplified
therapeutic scheme of oritavancin, and, to a lesser extent,
of dalbavancin, appears to be an appealing solution to the
economic burden represented by hospitalization, but the
impact of such therapies on global treatment costs needs to
be established [32].
8 Conclusion
The pharmacological profile of oritavancin, telavancin, and,
to a lesser extent, dalbavancin, demonstrates clear advan-
tages over that of conventional glycopeptides with respect to
their bactericidal character (oritavancin and telavancin),
activity against vancomycin-resistant strains (oritavancin),
or prolonged residence in the organism (oritavancin and
dalbavancin). However, this superiority over conventional
glycopeptides was not as clear in their clinical evaluation.
This discrepancy may be related to the general non-inferi-
ority design of registration studies, the planning and
reporting of which is sometimes reported as being subopti-
mal for anti-infective agents [167]. Moreover, these studies
mainly enrolled patients with mid-severity infections [146,
159, 168], against which the comparator is effective, and
thus the advantages of more powerful antibacterials do not
show through. Thus, superiority trials should be planned in
specific indications or situations [169, 170]. Likewise,
additional studies in more severe infections as well as
clinical experience in real-life situations will possibly help to
document these advantages and position these drugs in our
current arsenal. At this stage, one can already point out the
possibility of using oritavancin or dalbavancin for outpatient
therapy, which could contribute to containing costs,
improving quality of life, and adherence to the treatment, as
well as to reducing adverse reactions related to prolonged
intravenous therapy such as thrombophlebitis or catheter-
related bloodstream infections [32, 130, 134]. On the other
hand, their long half-life asks the question of how to manage
adverse effects [133], oritavancin being not extracted by
dialysis [171] and dalbavancin only by high-flux dialysers
[172]. Thus, among these three drugs, and based on current
knowledge of their respective safety profile, the clinician’s
choice should take into account specific safety concerns,
such as a possibly increased risk of osteomyelitis with ori-
tavancin, of nephrotoxicity and QTc interval prolongation
with telavancin, and of increased hepatic enzymes with
dalbavancin. Also, in this context, dalbavancin may show an
advantage by presenting a lower potential for drug interac-
tions or interference in laboratory testing than the other two
drugs [134]. As a result, further clinical experience is war-
ranted to better position each of these molecules in our
current arsenal and to define their potential in difficult-to-
treat infections in which they could reveal all of their
advantages.
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